Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26195406 | 0.86 | NOS1 (0.43) | NOS1RAB9AGLP1RCNR2KDR | |
| SCHEMBL128024 | 0.84 | NOS1 (0.44) | NOS1RAB9AGLP1RSMN1; SMN2CNR2 | |
| SCHEMBL9609561 | 0.81 | NOS1 (0.46) | NOS1RAB9ASMN1; SMN2CNR2KDR | |
| SCHEMBL14151845 | 0.79 | NOS1 (0.50) | NOS1RAB9ASMN1; SMN2KDRFDPS | |
| SCHEMBL126808 | 0.77 | NOS1 (0.43) | NOS1RAB9ASMN1; SMN2CNR2KDR | |
| SCHEMBL129440 | 0.77 | MLYCD (0.40) | NOS1FDPSALDH1A1TP53HTT | |
| SCHEMBL31581042 | 0.76 | SNCA (0.31) | SMN1; SMN2KDR | |
| SCHEMBL25933310 | 0.74 | NOS1 (0.40) | NOS1RAB9ACNR2 | |
| SCHEMBL28265326 | 0.74 | NOS1 (0.33) | NOS1GLP1RCNR2ALDH1A1TP53 | |
| SCHEMBL21843811 | 0.72 | NOS1 (0.39) | NOS1RAB9ASMN1; SMN2CNR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023164233-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | NOS1 1052/4885RAB9A 1335/4885GLP1R 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.